Indication
Deficiency of interleukin-1 receptor antagonist
Deficiency of interleukin-1 receptor antagonist is an exceedingly rare, life-threatening monogenic autoinflammatory disorder caused by biallelic loss-of-function mutations or deletions in the *IL1RN* gene. Read more about Deficiency of interleukin-1 receptor antagonist
2 drugs 2 manufacturers
Drugs that treat it
Common Deficiency of interleukin-1 receptor antagonist therapies.
ARCALYST (rilonacept)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDeficiency of interleukin-1 receptor antagonist is an exceedingly rare, life-threatening monogenic autoinflammatory disorder caused by biallelic loss-of-function mutations or deletions in the *IL1RN* gene.
This genetic defect results in the absence of functional interleukin-1 receptor antagonist protein, leading to unopposed interleukin-1 receptor signaling and uninhibited systemic inflammation.
Typically presenting in early infancy or within the neonatal period, the condition primarily targets the skeletal and integumentary systems.
Hallmarks include sterile multifocal osteomyelitis, periostitis, skeletal dysplasias, generalized pustular dermatitis, and marked elevation of acute-phase reactants, frequently occurring in the absence of persistent high-grade fevers.
- nih.gov
Deficiency of interleukin-1 receptor antagonist is an exceedingly rare, life-threatening monogenic autoinflammatory disorder caused by biallelic loss-of-function mutations or deletions in the *IL1RN* gene Hallmarks include sterile multifocal osteomyelitis, periostitis, skeletal dysplasias, generalized pustular dermatitis, and marked elevation of acute-phase reactants, frequently occurring in the absence of persistent high-grade fevers
- hee.nhs.uk
Deficiency of interleukin-1 receptor antagonist is an exceedingly rare, life-threatening monogenic autoinflammatory disorder caused by biallelic loss-of-function mutations or deletions in the *IL1RN* gene This genetic defect results in the absence of functional interleukin-1 receptor antagonist protein, leading to unopposed interleukin-1 receptor signaling and uninhibited systemic inflammation Hallmarks include sterile multifocal osteomyelitis, periostitis, skeletal dysplasias, generalized pustu...
- dermnetnz.org
This genetic defect results in the absence of functional interleukin-1 receptor antagonist protein, leading to unopposed interleukin-1 receptor signaling and uninhibited systemic inflammation Typically presenting in early infancy or within the neonatal period, the condition primarily targets the skeletal and integumentary systems
- nih.gov
Typically presenting in early infancy or within the neonatal period, the condition primarily targets the skeletal and integumentary systems
Personalize your experience
Follow Deficiency of interleukin-1 receptor antagonist and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.